menu
    • menu
    [{"orgOrder":0,"company":"TCG GreenChem","sponsor":"Shuttle Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Ropidoxuridine","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I","graph3":"TCG GreenChem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"TCG GreenChem \/ TCG GreenChem","highestDevelopmentStatusID":"6","companyTruncated":"TCG GreenChem \/ TCG GreenChem"},{"orgOrder":0,"company":"TCG Lifesciences","sponsor":"Sea Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"SPM-0404","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"TCG Lifesciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TCG Lifesciences \/ TCG Lifesciences","highestDevelopmentStatusID":"5","companyTruncated":"TCG Lifesciences \/ TCG Lifesciences"}]

    Find Clinical Drug Pipeline Developments & Deals by TCG Lifesciences

    Menu

    TCG Lifesciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TCG Lifesciences

                            India arrow
                            EPSC
                            Not Confirmed

                            TCG Lifesciences

                            India arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SPM-0404

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Recipient : Sea Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sea Pharmaceuticals Progresses Oral Neurotherapeutics with TCG GreenChem

                            Details : The collaboration aims to advance Sea's lead molecule SPM-0404 and a second-generation molecule SPM-0606, biologically active as dual AMPAR, KAINR antagonists.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 14, 2024

                            Lead Product(s) : SPM-0404

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Recipient : Sea Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TCG GreenChem

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            TCG GreenChem

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ropidoxuridine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Shuttle Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine

                            Details : Ropidoxuridine (also called IPdR), the lead clinical sensitizer drug candidate, sensitizes rapidly growing cancer cells and selective histone deacetylase (HDAC) inhibitors, to sensitize cancer cells and stimulate the immune system.

                            Product Name : IPdR Prodrug

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Ropidoxuridine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Shuttle Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth